Colombia vs Rwanda: HIV/AIDS deaths averted by antiretroviral therapy
Colombia
11,670 deaths
in 2023
Rwanda
13,299 deaths
in 2024
Colombia rank
21st
Rwanda rank
18th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Colombia
- Rwanda
How they compare
Rwanda currently reports 13,299 deaths against 11,670 deaths in Colombia, a difference of 1,629 deaths.
That makes Rwanda's figure about 1.1 times Colombia's.
The two have swapped places 2 times across 34 shared years of data; in 1990 it was Rwanda ahead.
Colombia ranks 21st and Rwanda ranks 18th of 157 countries.
Rwanda has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Colombia | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 1,534 deaths | 3,990 deaths | 2,456 deaths | Rwanda |
| 2010s | 6,492 deaths | 12,999 deaths | 6,507 deaths | Rwanda |
| 2020s | 10,904 deaths | 13,743 deaths | 2,839 deaths | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Colombia or Rwanda?
- Rwanda, at 13,299 deaths against 11,670 deaths in Colombia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Colombia and Rwanda?
- 1,629 deaths, with Rwanda ahead.
- How many years of comparable data are there for Colombia and Rwanda?
- 34 years are reported by both, from 1990 to 2023.
- How do Colombia and Rwanda rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Colombia ranks 21st and Rwanda ranks 18th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.